Evolent Health(US:EVH)2023-02-23 04:29Financial Performance - Q4 2022 revenue reached $382 million, a 54% year-over-year increase[8] - 2022 annual revenue totaled $1352 million, representing a 489% year-over-year growth[16] - Q4 2022 Adjusted EBITDA was $323 million, a 329% year-over-year increase[34] - 2022 Adjusted EBITDA was $1063 million, with a margin of 79% compared to 73% in 2021[34] Segment Performance - Clinical Solutions revenue for Q4 2022 was $2815 million, a 747% year-over-year increase[18] - Evolent Health Services revenue for Q4 2022 was $101 million, a 158% year-over-year increase[18] - Corporate overhead expenses decreased by 203% to $105 million[18] Debt and Cash Flow - Net debt to LTM Adjusted EBITDA was 25x, including five months of Surgery Management (IPG) Adjusted EBITDA[16, 36] - Available cash increased by $25 million in Q4[16] - Total debt was $4218 million, and net debt was $2703 million[36] Guidance - The company anticipates a 2023 revenue range of $192 billion to $196 billion[16] - The company anticipates a 2023 Adjusted EBITDA range of $180 million to $200 million[35]